检索结果-南通市图书馆

Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience

引用

Oncology Research 2024年第6期32卷 1031-1036页

作者： CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH lubomir sokol HAYDER SAEED JAVIER PINILLA SAMEH GABALLA Department of Internal Medicine University of South FloridaTampaFL33602USA College of Medicine University of South Florida MorsaniTampaFL33602USA H.Lee Moffitt Cancer Center and Research Institute TampaFL33612USA

Extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone *** bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s *** one trial has evaluated frontline BR prospectively in *** retrospective study reports outcomes among EMZL patients receiving frontline ***-five patients were included with a median age of 69 years(40–81).Five(20.0%)patients had stage Ⅰ/Ⅱ disease,and 20(80.0%)had stage Ⅲ/Ⅳ *** median number of cycles was 6.0(3.0–6.0).Maintenance rituximab was administered to 10(41.7%)*** response rate(ORR)was 100.0%(60.0%complete response,40.0%partial response).Medians of overall survival and progression-free survival were not *** estimated 2-year progression-free survival was 85.2%and overall survival was 100.0%.Four(16.6%)patients had infections related to treatment;3(12.0%)transformed to diffuse large B-cell lymphoma;5(20.8%)had a relapse or progression of EMZL;and 3(12.0%)died unrelated to *** is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.

关键词： Extranodal marginal zone lymphoma Bendamustine Rituximab Front-line therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Manifestations of gastrointestinal plasmablastic lymphoma: A case series with literature review

引用

World Journal of Gastroenterology 2014年第33期20卷 11894-11903页

作者： Lynette Luria Johnny Nguyen Jun Zhou Michael Jaglal Jane L Messina Domenico Coppola lubomir sokol Ling Zhang Department of Pathology University of South Florida Morsani College of Medicine Tampa FL 33612 United States. Department of Pathology Wayne State University School of Medicine Detroit MI 48202 United States Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa FL 33612 United States Department of Surgical Pathology H. Lee Moffitt Cancer Center and Research Institute Tampa FL 33612 United States Department of Hematopathology and Laboratory Medicine H. Lee Moffitt Cancer Center and Research Institute Tampa FL 33612 United States

Plasmablastic lymphoma (PBL) rarely occurs in the gastrointestinal (GI) tract with limited studies reported. We reviewed the clinical histories and pathology of four patients with GI PBL at our institute and similar case reports published in peer-reviewed journals. In our first case, a 40 year-old human immunodeficiency virus positive male presented with a hemorrhoid-like sensation, and was diagnosed with PBL via biopsy of a rectal mass. The second case involves a 65 year-old healthy male with bloody diarrhea who was found to have PBL in a resected sigmoid mass. The third patient was a 41 year-old male with a history of Crohn’s disease who presented with abdominal pain, diarrhea, and weight loss. A small intestinal mass (PBL) was removed. The fourth patient was a 65-year-old male who was found PBL after surgical resection of bowel for his florid Crohn’s disease. He later developed secondary acute myeloid leukemia. Clinical outcome was very poor in 3 out of 4 patients as reported in the literature. One patient survived chemotherapy followed by autologous transplant. The prototypical clinical presentation and variations of PBL can help create a more comprehensive differential diagnosis for GI tumors and establish an appropriate therapeutic guideline.

关键词： Plasmablastic lymphoma Undifferentiated carcinoma Non-Hodgkin lymphoma Diverse clinical manifestation and treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies

引用

Journal of Clinical and Translational Hepatology 2016年第2期4卷 143-150页

作者： Oluwatobi O.Ozoya lubomir sokol Samir Dalia Emergency and Trauma Center Tampa General HospitalTampaFLUSA Department of Hematological Malignancies H.Lee Moffitt Cancer CenterTampaFLUSA Oncology and Hematology Mercy Clinic JoplinJoplinMOUSA

Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic ***-Hodgkin's lymphoma is the most common hematological malignancy,and certain patients undergoing therapy are at increased risk of HBV ***,a monoclonal antibody,is well studied in HBV reactivation,but newer agents have been implicated as ***,we review novel agents suspected in HBV reactivation and effective strategies to prevent HBV *** years of literature were reviewed in order to better understand the reactivation rates of hepatitis B in patients with non-Hodgkin's ***-CD20 antibodies continue to be the main medications that can lead to HBV reactivation,and HBV reactivation rates have decreased with increased *** reactivation is uncommon when using other novel *** and lamivudine remain the agents of choice to prevent HBV reactivation in high risk *** conclusion,the immunosuppressive effect of NHL and its therapy provide a pathway for HBV reactivation,especially in patients treated with anti-CD20 *** many HBV positive patients are often excluded from clinical trials of novel agents in NHL,more aggressive post-market surveillance of new agents,welldesigned best practice advisories,and timely case reports are needed to reduce the incidence of HBV ***,large prospective investigations coupled with well-utilized best practice advisories need to be conducted to understand the impact of more potent novel NHL therapy on HBV reactivation.(C) 2016 The Second Affiliated Hospital of Chongqing Medical *** by XIA & HE Publishing *** rights reserved.

关键词： Hepatitis B virus HBV reactivation Non-Hodgkin's lymphoma Rituximab Anti-CD20 antibody Best practice advisories

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：